Browsing Centre for Genomics and Child Health by Author "Pade, C"
Now showing items 1-14 of 14
-
Behcet's patients' response to COVID-19 vaccination
Gokani, B; Sacoor, S; Leisegang, GR; Ogunkolade, W; Bibi, A; Grigoriadou, S; Pade, C; Gibbons, J; Senusi, A; Fortune, F (2023) -
The beta-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19
Usai, C; Gibbons, JM; Pade, C; Li, W; Jacobs, SRM; McKnight, A; Kennedy, PTF; Gill, US (2022) -
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Milojkovic, D; Reynolds, CJ; Sandoval, DM; Pieper, FP; Liu, S; Pade, C; Gibbons, JM; McKnight, A; Loaiza, S; Palanicawander, R (2023) -
Curbside particulate matter and susceptibility to SARS–CoV-2 infection
Miyashita, L; Foley, G; Semple, S; Gibbons, JM; Pade, C; McKnight, Á; Grigg, J (2023-11-01)Background: Biologic plausibility for the association between exposure to particulate matter (PM) less than 10 μm in aerodynamic diameter (PM10) and coronavirus disease 2019 (COVID-19) morbidity in epidemiologic studies ... -
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.
Abhishek, A; Peckham, N; Pade, C; Gibbons, JM; Cureton, L; Francis, A; Barber, V; Williams, JAE; Appelbe, D; Eldridge, L (2024-02)BACKGROUND: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 ... -
Generation of Novel Severe Acute Respiratory Syndrome Coronavirus 2 Variants on the B.1.1.7 Lineage in 3 Patients With Advanced Human Immunodeficiency Virus-1 Disease
Riddell, AC; Kele, B; Harris, K; Bible, J; Murphy, M; Dakshina, S; Storey, N; Owoyemi, D; Pade, C; Gibbons, JM (2022) -
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
Reynolds, CJ; Gibbons, JM; Pade, C; Lin, K-M; Sandoval, DM; Pieper, F; Butler, DK; Liu, S; Otter, AD; Joy, G (2022) -
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19
Astbury, S; Reynolds, CJ; Butler, DK; Munoz-Sandoval, DC; Lin, K-M; Pieper, FP; Otter, A; Kouraki, A; Cusin, L; Nightingale, J (2022) -
Kerbside Particulate Matter and Susceptibility to SARS-CoV-2 Infection
Miyashita, L; Foley, G; Semple, S; Gibbons, J; Pade, C; Mcknight, A; Grigg, J (Elsevier, 2022-01-01) -
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection
Milighetti, M; Peng, Y; Tan, C; Mark, M; Nageswaran, G; Byrne, S; Ronel, T; Peacock, T; Mayer, A; Chandran, A (2023) -
Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity.
Altmann, DM; Reynolds, CJ; Joy, G; Otter, AD; Gibbons, JM; Pade, C; Swadling, L; Maini, MK; Brooks, T; Semper, A (2023-08-23)Among the unknowns in decoding the pathogenesis of SARS-CoV-2 persistent symptoms in Long Covid is whether there is a contributory role of abnormal immunity during acute infection. It has been proposed that Long Covid is ... -
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection
Captur, G; Moon, JC; Topriceanu, C-C; Joy, G; Swadling, L; Hallqvist, J; Doykov, I; Patel, N; Spiewak, J; Baldwin, T (2022) -
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Mcknight, A; Pade, C; Gibbons, J (Nature Research, 2021-11-10) -
Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections
Chandran, A; Rosenheim, J; Nageswaran, G; Swadling, L; Pollara, G; Gupta, RK; Burton, AR; Guerra-Assuncao, JA; Woolston, A; Ronel, T (2022)